Medicare Enrolled

Dr. Michael Porubcin, MD

Hematology & Oncology · Moline, IL
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Consulting-driven
600 JOHN DEERE ROAD, Moline, IL 61265
3097794200
In practice since 2006 (20 years)
NPI: 1770553349 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Porubcin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Porubcin? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Porubcin

Dr. Michael Porubcin is a hematology & oncology specialist in Moline, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Porubcin performed 1,694 Medicare services across 687 unique beneficiaries.

Between the years covered by Open Payments, Dr. Porubcin received a total of $30,870 from 59 pharmaceutical and/or device companies across 314 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Porubcin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 39% volume in IL $30,870 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,694
Medicare services
Top 39% in IL for hematology & oncology
687
Unique beneficiaries
$73
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~85 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
1,319 $67 $224
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
191 $107 $302
New patient office visit, complex (60-74 min) 58 $133 $428
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
50 $44 $150
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
43 $89 $344
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
33 $20 $90
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$30,870
Total received (2018-2024)
Avg $4,410/year across 7 years
Top 17% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
59
Companies
314
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$23,262 (75.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,451 (24.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$157 (0.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$4,806
2023
$913
2022
$901
2021
$2,760
2020
$1,788
2019
$5,296
2018
$14,406

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$2,017
Janssen Biotech, Inc.
$362
Myriad Genetic Laboratories, Inc.
$335
ABBVIE INC.
$262
AstraZeneca Pharmaceuticals LP
$222
Mirati Therapeutics, Inc.
$145
Astellas Pharma US Inc
$139
Daiichi Sankyo Inc.
$132
Stemline Therapeutics Inc.
$121
GENZYME CORPORATION
$114
Regeneron Healthcare Solutions, Inc.
$98
E.R. Squibb & Sons, L.L.C.
$91
GlaxoSmithKline, LLC.
$86
Genmab U.S., Inc.
$83
Genentech USA, Inc.
$76
SERVIER PHARMACEUTICALS LLC
$56
Exelixis Inc.
$54
Merck Sharp & Dohme LLC
$53
PFIZER INC.
$43
Celgene Corporation
$33
SOBI, INC
$32
Takeda Pharmaceuticals U.S.A., Inc.
$25
Agios Pharmaceuticals, Inc.
$24
Mirum Pharmaceuticals, Inc.
$23
Octapharma USA, Inc.
$21
Eisai Inc.
$21
Geron Corporation
$20
Bayer Healthcare Pharmaceuticals Inc.
$19
Gilead Sciences, Inc.
$18
PharmaEssentia USA Corporation
$17
Alexion Pharmaceuticals, Inc.
$17
Alnylam Pharmaceuticals Inc.
$16
Ipsen Biopharmaceuticals, Inc
$16
Incyte Corporation
$14
Top 3 companies account for 56.5% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$6,637
Novartis Pharmaceuticals Corporation
$6,174
Pharmacyclics LLC, An AbbVie Company
$4,976
TESARO, Inc.
$2,732
GlaxoSmithKline, LLC.
$1,774
Eisai Inc.
$1,400
Janssen Biotech, Inc.
$650
Genentech USA, Inc.
$614
BeiGene, Ltd.
$525
Daiichi Sankyo Inc.
$520
GENZYME CORPORATION
$474
E.R. Squibb & Sons, L.L.C.
$373
Incyte Corporation
$365
Myriad Genetic Laboratories, Inc.
$361
Lilly USA, LLC
$330
ABBVIE INC.
$262
Seagen Inc.
$206
Amgen Inc.
$190
Mirati Therapeutics, Inc.
$163
Takeda Pharmaceuticals U.S.A., Inc.
$142
Astellas Pharma US Inc
$139
Stemline Therapeutics Inc.
$135
HealthMyne, Inc.
$132
BeiGene USA, Inc.
$121
PFIZER INC.
$120
Jazz Pharmaceuticals Inc.
$115
Ipsen Biopharmaceuticals, Inc
$102
Regeneron Healthcare Solutions, Inc.
$98
JAZZ PHARMACEUTICALS INC.
$97
Merck Sharp & Dohme Corporation
$88
Genmab U.S., Inc.
$83
Exelixis Inc.
$81
SERVIER PHARMACEUTICALS LLC
$56
Merck Sharp & Dohme LLC
$53
Alexion Pharmaceuticals, Inc.
$51
Celgene Corporation
$50
Agios Pharmaceuticals, Inc.
$38
SOBI, INC
$32
Gilead Sciences, Inc.
$30
PUMA BIOTECHNOLOGY, INC.
$30
NOVARTIS PHARMACEUTICALS CORPORATION
$29
Array BioPharma Inc.
$25
Karyopharm Therapeutics Inc.
$24
Mirum Pharmaceuticals, Inc.
$23
Apellis Pharmaceuticals, Inc.
$23
Octapharma USA, Inc.
$21
EISAI INC.
$20
Geron Corporation
$20
Verastem, Inc.
$19
Bayer Healthcare Pharmaceuticals Inc.
$19
EMD Serono, Inc.
$18
PharmaEssentia USA Corporation
$17
Alnylam Pharmaceuticals Inc.
$16
Shire North American Group Inc
$15
Janssen Pharmaceuticals, Inc
$14
Puma Biotechnology, Inc.
$13
Rigel Pharmaceuticals, Inc.
$12
Sysmex Inostics Inc
$11
Bayer HealthCare Pharmaceuticals Inc.
$11
Top 3 companies account for 57.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · ALUNBRIG · AUGTYRO · Alecensa · Aliqopa · Avastin · BESREMI · BRUKINSA · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CARVYKTI · CYRAMZA · Cabometyx · Cholbam · Columvi · Copiktra · DARZALEX · DOPTELET · ELAHERE · ELIQUIS · ELITEK · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · Empaveli · Enhertu · Epkinly · Erleada · FASLODEX · Fabhalta · GAZYVA · GIVLAARI · HealthMyne · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INVOKANA · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MYRISK · NERLYNX · Neulasta · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · OPDIVO · OPDUALAG · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · Padcev · REBLOZYL · RYDAPT · RYTELO · Rituxan · SARCLISA · SCEMBLIX · SYNAGIS · Stivarga · TAGRISSO · TASIGNA · TAXOTERE · TECENTRIQ · TECVAYLI · TIBSOVO · Tavalisse · Tazverik · Tecentriq · Tibsovo · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VPRIV · VYXEOS · Venclexta · Voranigo · XALKORI · XGEVA · XPOVIO · XTANDI · Xospata · Xtandi · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (75%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.

Looking for a hematology & oncology specialist in Moline?
Compare hematology & oncology specialists in the Moline area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
5
Per 100K population
3.5
County median income
$66,768
Nearest hospital
GENESIS HLTH SYSTEM DBA GENESIS MDL CTR-ILLINI
4.1 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Porubcin is a clinical cardiology specialist, with moderate Medicare volume, with consulting-driven industry engagement in the top 17% of IL peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Porubcin experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Porubcin performed 1,319 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Porubcin receive payments from pharmaceutical companies?
Yes. Dr. Porubcin received a total of $30,870 from 59 companies across 314 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Porubcin's costs compare to other hematology & oncology specialists in Moline?
Dr. Porubcin's average Medicare payment per service is $73. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Porubcin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →